UP Oncolytics Earns Innovation Voucher for Cancer Drug Development
UP Oncolytics, a forward-thinking biotech company located within the Helix 51 biomedical incubator, is making significant strides in the battle against aggressive forms of brain cancer. Recently, they were awarded an Illinois Innovation Voucher grant for $75,000, which will propel their collaboration with Rosalind Franklin University forward in their exciting mission.
Understanding Glioblastoma Multiforme
Glioblastoma Multiforme (GBM) is recognized as one of the most challenging forms of malignant brain cancer, leading to devastating outcomes for many. It is particularly concerning, as it stands as the primary cause of cancer-related fatalities among men under the age of 40 in the United States. With approximately 13,000 new diagnoses each year, it becomes critical to address the lack of effective treatments, as the median survival time remains a mere 14 months, with the five-year rate barely touching 7.1%.
Impact of the Illinois Innovation Voucher Grant
This grant, granted by the Illinois Department of Commerce and Economic Opportunity (DCEO) and executed by the Illinois Science & Technology Coalition (ISTC), aims to bolster collaboration between local universities and emerging small businesses. With this support, UP Oncolytics can now undertake essential Investigational New Drug (IND) experiments at the state-of-the-art research laboratories at RFU. These experiments are pivotal for developing their initial treatment candidate designed specifically for GBM.
Statements from UP Oncolytics Leadership
Reflecting on this achievement, Dr. Richard Rovin, CEO of UP Oncolytics and a seasoned neurosurgeon, expressed his gratitude. He emphasized the importance of this recognition, citing how it would provide crucial support in advancing a potential therapy for patients suffering from GBM. "I am hopeful there will be an effective treatment in the near future for the patients afflicted by this disease," he stated, demonstrating his commitment to patient care.
Support from ISTC and DCEO
Joseph DiMario, PhD, serving as RFU's executive vice president for research, acknowledged the significance of the grant. He emphasized the positive impact of supporting an early-stage cancer biotech company like UP Oncolytics, which is striving to introduce innovative therapeutic treatments. His endorsement underlines the collaborative effort between academia and industry in tackling this formidable disease.
Expanding oncolytic virus research
UP Oncolytics has recently established an exclusive license agreement for a promising therapy involving an oncolytic virus, originating from Advocate Health. In 2025, they not only secured this innovative technology but also garnered an NIH SBIR Fast Track grant, along with an FDA Orphan Drug designation that extends to malignant gliomas, encompassing a wider variety of brain cancers, including GBM. This pivotal progression signals a brighter future for cancer treatments.
Building a Strong Advisory Team
The company has augmented its oncology expertise by bringing on experienced board members. Dr. Gary Gordon, who trained at Johns Hopkins, has previously served as the vice president of clinical oncology at AbbVie. Michael Rosen is another vital addition, with his rich background, having held executive roles within prestigious organizations such as Pfizer, Bristol-Myers Squibb, and Searle. Their expertise will guide UP Oncolytics as it navigates the complex landscape of cancer drug development.
About Rosalind Franklin University
Rosalind Franklin University of Medicine and Science, founded in 1912, is dedicated to enhancing global wellness through interprofessional education in health and biomedical domains, alongside advancing knowledge to improve public health outcomes. Centered in Chicago, RFU honors the legacy of Dr. Rosalind Franklin, whose pivotal work helped unravel the structure of DNA. The university is recognized for its contributions to a variety of research areas, including neuroscience, diabetes, and inherited disorders, cumulatively fostering an environment conducive to innovation.
About UP Oncolytics
Discover more about UP Oncolytics at their official website.
Frequently Asked Questions
What is GBM?
GBM stands for Glioblastoma Multiforme, a particularly aggressive type of brain cancer.
What is the purpose of the Illinois Innovation Voucher grant?
This grant supports collaborations between state universities and small businesses, helping to advance innovative projects like UP Oncolytics’ cancer research.
Who leads UP Oncolytics?
Dr. Richard Rovin is the CEO of UP Oncolytics, bringing expertise in neurosurgery to the team.
What kind of therapies is UP Oncolytics developing?
They are primarily focused on developing a novel treatment for Glioblastoma Multiforme, employing cutting-edge technology involving oncolytic viruses.
How can UP Oncolytics impact cancer treatment?
By developing innovative therapies for GBM, UP Oncolytics aims to improve survival rates and quality of life for patients diagnosed with this aggressive cancer.
